Archer Investment Corp Sells 790 Shares of United Therapeutics Corporation $UTHR

Archer Investment Corp cut its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 70.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 325 shares of the biotechnology company’s stock after selling 790 shares during the quarter. Archer Investment Corp’s holdings in United Therapeutics were worth $93,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $29,000. SVB Wealth LLC purchased a new stake in United Therapeutics during the first quarter valued at about $32,000. Geneos Wealth Management Inc. increased its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. Brooklyn Investment Group raised its holdings in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 98 shares during the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of United Therapeutics in the first quarter worth about $60,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on UTHR. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Wednesday. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. HC Wainwright lifted their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Stock Up 0.0%

Shares of NASDAQ:UTHR opened at $474.82 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $485.32. The firm has a fifty day simple moving average of $439.78 and a two-hundred day simple moving average of $355.47. The stock has a market capitalization of $20.44 billion, a P/E ratio of 17.99, a PEG ratio of 4.96 and a beta of 0.77.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period last year, the company earned $6.39 EPS. On average, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $400.56, for a total value of $9,012,600.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 519,935 shares of company stock worth $224,879,377. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.